FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.

from Latest articles from Cancer Therapy Advisor Gastrointestinal Cancers https://ift.tt/2MT0W6w